PATENTS

Issued

(1) METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE.  Patent no. US 9,040,662 B2.  Date of patent: May, 26, 2015

(2) COMPOSITIONS COMPRISING IL-7 RECEPTOR LIGANDS. Patent no. US9,266,937 B2. Date of patent: Feb. 23, 2016

(3) COMPOSITIONS AND METHODS FOR PURIFYING BAX.  Patent no. US 9,403,888.  Date of patent: August 2, 2016

Applied

(1) CHAPERONIN CONTAINING TCP-1 (CCT) INHIBITION FOR TREATING CANCER for which an application for a Provisional Patent was filed on Dec. 7, 2015.

(2) METHODS AND COMPOSITIONS FOR THERANOSTIC NANOPARTICLES TECHNICAL FIELD for which an application for U.S. Letters Patent was filed on April 28, 2015.

(3) METHODS AND COMPOSITIONS COMPRISING A CT20 PEPTIDE for which an application for U.S. Letters Patent was filed on July 18, 2014 as Serial No. 62/026,564 and an international application filed July 9, 2015.

Licensing Agreements

A licensing agreement for patents (above) has been signed with SEVA Therapeutics, Inc.

 

PEER-REVIEWED PUBLICATIONS (total 53)

Published since joining UCF  (*UCF student researchers)

  1. Carr A*, AS Khaled, R Bassioun, O Flores, D Nierenberg*, H Bhatti, P Vishnubhotla, JM Perez, S Santra, and AR Khaled. 2017. Targeting Chaperonin Containing TCP1 (CCT) as a Molecular Therapeutic for Small Cell Lung Cancer. Oncotarget. 8(66):110273-88.
  2. Showalter A*, A Limaye*, JL Oyer, R Igarashi, C Kittipatarin, AJ Copik1, and AR Khaled. 2017. Cytokines in Immunogenic Cell Death: Applications for Cancer Immunotherapy. Cytokine. 97:123-132.
  3. Flores O*, S Santra,C Kaittanis, R Bassiouni*, AS Khaled, AR Khaled, J Grimm, and JM Perez. 2017. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer. Theranostics. 7(9):2477-2494.
  4. Bassiouni R*, K Nemec, A Iketani, O Flores*, A Showalter*, RW Sprung, C Kaittanis, P Vishnubhotla, AS Khaled, JM Perez, AR Khaled. 2016. Chaperonin containing-TCP-1 protein level in breast cancer cells predicts therapeutic application of a cytotoxic peptide.  Clin Cancer Res. 22(17):4366-79
  5. Lee MW, R Bassiouni*, A Iketani, JM Perez and AR Khaled. 2014. The CT20 peptide:  More than a piece of Bax. Cancer Cell and Microenvironment.  1:e266
  6. Lee MW, R Bassiouni*, NA Sparrow*, A Iketani, RJ Boohaker*, C Moskowitz*, P Vishnubhotla, AS Khaled, J Oyer, A Copik, C Fernandez-Valle, JM Perez and AR Khaled. 2014. The CT20 Peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruption. Cell Death and Disease.   22:5 e1249
  7. Garg P*, KN Nemec, AR Khaled, SA Tatulian. 2013. Transmembrane pore formation by the carboxyl terminus of Bax protein. Biochim Biophys Acta. 1828(2):732-42
  8. Tatulian SA, P Garg*, KN Nemec, AR Khaled. 2012. Molecular basis for membrane pore formation by Bax protein carboxyl terminus.  Biochemistry 51(46):9406-19
  9. Ruppert SM*, W Li, G Zhang*, AL Carlson, A Limaye*, SK Durum, AR Khaled. 2012. The major isoforms of Bim contribute to distinct biological activities that govern the processes of autophagy and apoptosis in interleukin-7 dependent lymphocytes. Biochim Biophys Acta. 1823(10):1877-93.
  10. Boohaker RJ*, G Zhang*, MW Lee, KN Nemec, S Santra, JM Perez, AR Khaled. 2012. Rational development of a cytotoxic peptide to trigger cell death. Mol Pharm. 9(7):2080–93
  11. Boohaker RJ*, MW Lee, P Vishnubhotla, JM Perez, AR Khaled. 2012. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 1;19(22):3794-804.
  12. Altomare DA, AR Khaled. 2012. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem.1;19(22):3748-62.
  13. Ruppert SM*, M Chehtane*, G Zhang*, H Hu*, X Li, AR Khaled. 2012. JunD/AP-1-mediated gene expression promotes lymphocyte growth dependent on interleukin-7 signal transduction.  PLoS One. 2012;7(2):e32262. Epub 2012 Feb 23.
  14. Boohaker RJ*, G Zhang*, A Loosely, KN Nemec and AR Khaled. 2011. BAX supports the mitochondrial network, promoting bioenergetics in Non-Apoptotic Cells. AJP: Cell Physiology. 300(6):C1466-1478
  15. Kittipatarin C*, W Li, SK Durum, AR Khaled. 2010. Cdc25A-driven proliferation regulates CD62L levels and lymphocyte movement in response to interleukin-7. Exp Hematol. 38(12):1143-56]
  16. Kittipatarin C*, N Tschammer* and AR Khaled. 2010. The Activity of LCK upon STAT5 can differentially modulate Interleukin-7 signaling in CD4 and CD8 T cells. Immunol Letts. 131(2):170-81.
  17. Chehtane M* and AR Khaled. 2010. Interleukin-7 mediates glucose utilization in lymphocytes through transcriptional regulation of the Hexokinase II gene expression. AJP: Cell Physiol 298(6):C1560-71.
  18. Kittipatarin C* and AR Khaled. 2009. Ex vivo expansion of memory CD8 T-cells from lymph nodes or spleen through in vitro culture with interleukin-7. J. Immunol Methods. 15;344(1):45-57.
  19. Nemec KN and AR Khaled. 2008. Therapeutic Modulation of Apoptosis: Targeting the BCL-2 family at the interface of the mitochondrial membrane. Yonsei Med J. 49(5):689-97.
  20. Grenier AD*, K Abu-ihweij*, G Zhang, S Ruppert*, RJ Boohaker*, E Slepkov, K Pridemore, JJ Ren, L Fliegel, and AR Khaled. 2008. Apoptosis-induced alkalinzation by the Na+/H+ exchanger isoforms 1 is mediated through phosphorylation of amino acids Ser726 and Ser729. Am J Physiol Cell Physiol. 295(4):C883-96.
  21. Kaur N, J Delcros, M Chehtane*, N Tschammer*, A Khaled and O Phanstiel. 2008. A comparison of Chloroambucil- and Xylene-containing polyamines leads to improved ligands for accessing the polyamine transporter. J. Med. Chem. 51(5):1393-401.
  22. Kittipatarin C* and AR Khaled. 2007. Interlinking Interleukin-7. Cytokine 39:75-83.
  23. Xie S, P Cheng, G Liu, Y Ma, J Zhao, M Chehtane*, AR Khaled, O Phantstiel, and C Wang. 2007. Synthesis and bioevaluation of the N-(Arylalkyl)-homospermidine conjugates.  BMCL  17(16):4471-5.
  24. Iacovelli J, J Lopera, M Bott, E Baldwin, A Khaled, N Uddin, and C Fernandez-Valle. 2007. Serum and forskolin cooperate to promote G1 progression in Schwann cells by differentially regulating cyclin D1, cyclin E1, and p27 expression. GLIA 55(16):1638-47..
  25. Kittipatarin C*, W.Q. Li, D Bulavin, SK Durum and A.R. Khaled. 2006. Cell Cycling Through Cdc25A: Transducer of Cytokine Proliferative Signals.  Cell Cycle. 5:907-12.
  26. Li WQ, Q Jiang, E Aleem, P Kaldis, AR Khaled, SK Durum. 2006. IL-7 promotes T cell proliferation through destabilization of p27Kip1. J Exp Med. 203(3):573-82.
  27. Kotha A, M Sekharam, L Cilenti, K Siddiquee, A Khaled, AS Zervos, B Carter, J Turkson and R Jove. 2006. Resveratrol inhibits Src and Stat3 and induces the apoptosis of malignant cells containing activated Stat3. Mol Can Ther. (3):621-9.
  28. Khaled A, S Guo, F Li, P Guo. 2005. Controllable Self-Assembly of Nanoparticles for Specific Delivery of Multiple Therapeutic Molecules to Cancer Cells Using RNA Nanotechnology.  Nano Lett. 14;5(9):1797-1808
  29. Jiang Q, WQ Li, FB Aiello, R Mazzucchelli, B Asefa, AR Khaled, SK Durum. 2005. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 16(4-5):513-33.
  30. 30. Khaled AR, DV Bulavin, C Kittipatarin*, WQ Li, KM. Alvarez, K Kim, HA Young, AJ Fornace, and SK Durum. Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biology 169[5]:755-63.
  31. Jiang Q, WQ Li, RR Hofmeister, HA Young, DR Hodge, JR Keller, AR Khaled, SK Durum. 2004. Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members. Mol Cell Biol. 24(14):6501-13.
  32. Ashktorab H, S Frank, AR Khaled, S Durum, B Kifle, and DT Smoot. 2004. Bax translocation and mitochondrial fragmentation induced by H. pylori. Gut 53:805-13.
  33. Li WQ, Q Jiang, AR Khaled, JR Keller, and SK Durum. 2004. Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival. J Biol Chem. 279(28):29160-6
  34. Jiang Q, N Benbernou, O Chertov, AR Khaled, J Wooters and SK Durum. 2004. IL-7 induces tyrosine phosphorylation of clathrin heavy chain. Cell Signal 16:281-6.
  35. Khaled AR and SK Durum. 2003. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol. Rev. 193(1) :48-57.
  36. Kim K, AR Khaled, D Reynolds, HA Young, CK Lee, and SK Durum. 2003. Characterization of an interleukin-7-dependent thymic cell line derived from a p53-/- mouse. J Immunol. Methods  274:177-184

Published during post-doctoral training from 1997-2002

  1. Khaled AR, WQ Li, J Huang, TJ Terry, AS Khaled, CL Mackall, K Muegge and SK Durum. 2002. Bax deficiency partially corrects IL-7 receptor-alpha deficiency.  Immunity 17:561-73.
  2. Khaled AR and SK Durum. 2002. Lymphocide. Death in the absence of cytokine signaling controls lymphoid homeostasis.  Nature Rev. Immunol.  2:817:830.
  3. Khaled, AR and SK Durum. 2002. The role of cytokines in lymphocyte homeostasis. Biotechniques, Oct. 2002 Supplement: 40-5.
  4. Szocinski JL, AR Khaled, J Hixon, D Halverson, S Funakoshi, WC Fanslow, A Boyd, DD Taub, SK Durum, CB Siegall, DL Longo, and WJ Murphy. 2002. Activation induced cell death of aggressive histology lymphomas by CD40 stimulation: Bax.  Blood 100:217-223.
  5. Khaled AR and SK Durum. 2001. From cytosol to mitochondria: the Bax translocation story.  J. Biochem. Mol. Biol. 34(5):391-394.
  6. Khaled AR, AN Moor, L Aiqun, K Kim, DK Ferris, RJ Fisher, L Fliegel, and SK Durum. 2001. Trophic factor withdrawal: p38 MAP kinase activates NHE1 inducing intracellular alkalinization.  Mol. Cell. Biol. 21(22):7545-7557.
  7. Khaled AR, DA Reynolds, HA Young, CB Thompson, K Muegge and SK Durum. 2001. IL-3 withdrawal induces an increase in mitochondrial membrane potential unrelated to the Bcl-2 family: Roles of intracellular pH, ADP transport and F0F1-ATPase. JBC 276(9): 6453-62.
  8. Welniak LA, AR Khaled, M Anver, D Reynolds, K Komschlies, R Wiltrout, H Young, R Blazar, S Durum, and WJ Murphy. 2001. Non-Immune action of interleukin-7: Intestinal crypt cells of interleukin-receptor deficient mice are highly sensitive to g-irradiation damage. J. Immunol. 166: 2923-2928.
  9. Khaled AR, K Kim, R Hofmeister, K Muegge, and SK Durum. 1999. Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH.  Proc.Natl. Acad. Sci., USA. 96(25): 14476-14478.
  10. Hofmeister R, AR Khaled, N Benbernou, E Rajnavolgyi, K Muegge, and SK Durum. 1999. IL-7. Physiological roles and mechanisms of action. Cyto. Growth Factor Rev. 10:41-60.

Published as a pre-doctoral student from 1992-1997

  1. Khaled AR, E Butfiloski, B Villas, E Sobel and J Schiffenbauer. 1999.  Aberrant expression of the NF-kB and IkB proteins in B cells from motheaten viable mice.  Autoimmunity 30:115-128.
  2. Khaled AR, E Butfiloski, E Sobel and J Schiffenbauer. 1998. Functional consequences of the SHP1 defect in motheaten viable mice: Role of NF-kB. Cell. Immunol. 185:49-58.
  3. Khaled AR, E Butfiloski, E Sobel and J Schiffenbauer. 1998. Use of phosphorothioate-modified deoxyoligonucleotides to inhibit NF-kB expression and lymphocyte function. Clin. Immunol. Immunopathol. 86:170-179.
  4. Khaled AR, L Soares, E Butfiloski, I Stekman, E Sobel and J Schiffenbauer. 1997. Inhibition of p50 subunit of NF-kB by antisense oligodeoxynucloetides reduces NF-kB expression and immunoglobulin synthesis in murine B cells.  Clin. Immunol. Immunopathol. 83:254-263.

Published as a research associate/technician 1987-1992

  1. Liebling MR, J Nishio, A Rodriguez, LH Siegel, T Jin, and J Louie. 1993. The polymerase chain reaction for the detection of Borrelia burgdorferi in human body fluids.  Arth. Rheum.  36:665-675.
  2. Keller MA, L Gendreau-Reid, DC Heiner, A Rodriguez, and JA Short. 1988. IgG4 in human colostrom and human milk: continued local production or selective transport from serum.  Acta. Paediatr. Scad.  77:24-29.
  3. 3. Keller MA, A.L.Rod(g)riguez, S Alvarez, NC Wheeler, and D Reisinger. 1987. Transfer of tuberculin immunity from mother to infant. Pediatr. Res. 22:277-281

 

Fictional publications

Rodriguez A.  “Broken Vows”.  In Renunciates of Darkover, ed. Marion Zimmer Bradley, Daw Books, New  York, N.Y. 1991

 

ABSTRACTS (total 45)

Published since joining UCF (*UCF student researchers)

  1. Flores O, D Nierneberg, A Carr, R Bassiouni, A Limaye, S Santra, C Kaittanis, JM Perez, AR Khaled. Peptide power: A PSMA-targeted CT20 nanoparticle to fight prostate cancer. . [abstract]. In: Proceedings of the 108th Annual Meeting of the American Association for Cancer Research; Washington DC. Cancer Research 77(13 Supplement):3241-3241
  2. Carr A, AS Khaled, R Bassiouni, AR Khaled. CT20p as a therapeutic for lung cancer with elevated chaperoning containing TCP1 (CCT) expression levels. [abstract]. In: Proceedings of the 108th Annual Meeting of the American Association for Cancer Research; Washinbgton DC. Cancer Research 77(13 Supplement):4895-4895
  3. Khaled AR, Amr S. Khaled, Rania Bassiouni, Priya Vishnubhotla. Chaperonin containing-TCP-1 protein level in breast cancer cells predicts therapeutic application of a cytotoxic peptide. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4121.
  4. Khaled AR, Limaye A, Bassiouni R, Showalter A, Oyer J, Pandey V, Igarashi R, Altomare DA, Copik AJ. Enhancing the immunogenicity of breast cancer cells to stimulate innate immunity and augment the effects of cellular immunotherapy. [abstract]. In: Proceedings of the 38 Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-04-12.
  5. Vishnubhotla P, Khaled AR, Khaled AS, Perez JM, Bassiouni R, Flores O, Nierenberg D. The dynamic duo: A breast cancer-targeting nanoparticle loaded with a cytotoxic peptide as a treatment for metastatic disease. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-03-02.
  6. Khaled AS, Vishnubhotla P, Khaled AR, Bassiouni R. Cutting the ties that bind: Targeting chaperonin-containing T-complex (CCT) for therapeutic intervention in the treatment of advanced stage breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-04-04.
  7. Khaled A, R Bassiouni*, A Limaye*, J Oyer, R Igarashi, O Flores*, J Perez and A Copik. Use of a cytotoxic peptide as an immunotherapeutic agent in the treatment of metastatic breast cancer 2015. J. Immunol  94 (1):214.14
  8. P Vishnubhotla, A Khaled, R Bassiouni*, O Flores*, JM Perez, AR Khaled. Chaperonin-containing T-complex (CCT) is a novel target for treatment of metastatic breast cancer. 2015. J Clin Oncol 33(5):e13530
  9. Limaye A*, R Bassiouni*, J Oyer, RW Igarashi, O Flores*, JM Perez, A Copik, and AR Khaled. Use of a cytotoxic peptide that induces immunogenic cell death to engage innate immunity in the treatment of metastatic breast cancer. 2014. Cancer Imm Res 3:A47
  10. Limaye A*, A Iketani, R Boohaker*, J Oyer, K Nemec, M Solh, A Copik, and AR Khaled. IL-7tv, a Modified Interleukin-7 protein, is a potent agent for immune reconstitution. 2013. Cytokine 63(2):282.
  11. Vishnubhotla P, RJ Boohaker, MW Lee, KN Nemec, A Khaled, S Santra, GM Perez, JM Perez, AR Khaled. Preclinical testing using a novel CT20p peptide-nanoparticle combination in breast cancer. 2013 Cancer Res 73(24):P6-04-13
  12. Garg P*, SA Tatulian, AR Khaled, KN Nemec. Biophysical Characterization of Peptide Membrane Interactions and Membrane Permeabilization. 2011. Biophysical J 100[3]:40.
  13. Kittipatarin C*, N Tschammer,* and AR Khaled. The Interaction of LCK and the CD4 Co-receptor alters the dose response of T-cells to interleukin-7. 2010.  Cytokine 52[1-2):14.
  14. Boohaker RJ*, G Zhang*, A Loosley, K Nemec, AR Khaled. Compartmentalization of BCL2 Family proteins mediated by organelle lipid membranes. 2010 Biophysical J 98(3):379A.
  15. Nemec KN, RJ Boohaker*, AR Khaled. Biophysical Insights into Bax oligomerizatiojn and memberane insertion. 2010 Biophysical J 98(3):464A
  16. Chehtane M* and AR Khaled. Interleukin-7 controls glucose uptake in T-lymphocytes by regulating hexokinse II gene expression. 2008. Cytokine 43[3]:288.
  17. Tschammer N*, TL Selby, AR Khaled. The membrane-binding activity of the apoptotic protein, BAX, is regulated through novel intermolecular interactions. 2007. Cytokine 39[1]:42-3.
  18. Kittipatarin C*, AR Khaled. Interleukin-7 Drives the Homeostatic Proliferation of T-cells through the Activity of Cdc25A. 2007. Cytokine 39[1]:21.
  19. Khaled AR, C Kittipatarin*, D Bulavin, WQ Li, K Kim, H Young, A Fornace, SK Durum. Cytokine-driven cell cycling is mediated through Cdc25A. 2005. FASEB J 19 (5):A1515.
  20. N Tschammer*, PX Guo and AR Khaled. Use of the bacteriophage phi29 packaging RNA as nanovehicle for targeted delivery of therapeutic RNAs to CD4 T cells. 2005.  FASEB J 19 (5):A1405.
  21. Khaled A, A Grenier*, M Alvarez, D Bulavin, WQ Li, K Kim, AJ Fornace and S.K. Durum. G1 arrest follows loss of cytokine signaling through degradation of Cdc25A, mediated by p38 MAPK. 2004. Nature Biotech. Short Report 15:107.
  22. Khaled A, WQ Li, and SK Durum. Death in the absence of cytokine signaling: Lessons learned from BAX/IL-7 receptor double deficient mice. 2003. FASEB 17[7]: C247.
  23. Li WQ, Q Jiang, A Khaled and S Durum. Interleukin (IL)-7 activates PI3 kinase pathway and inactivates Bad both of which are associated with cell survival. 2003. FASEB 17[7]: C294

Published during post-doctoral training from 1997-2002

  1. Khaled AR and SK Durum. Death in the absence of trophic factor signaling: Lessons learned from Bax/IL-7 receptor deficient mice. 2002. J. Interf. Cyto. Res. 22: S-67-68.
  2. Li, WQ, AR Khaled, and SK Durum. Interleukin-7 (IL)-7 induces AKT activation and Bad phosphorylation which are associated with T cell survival and proliferation. 2002. J. Interfer. Cyto. Res. 22 (Suppl 1):S-106.
  3. Khaled AR and SK Durum. Loss of the trophic factor signaling during thymocyte development: on the pathway to death through intracellular alkalinization and Bax activation. 2002.  FASEB 16 [4]: A341.
  4. Durum SK, K Muegge, and AR Khaled. Bax deletion restores thymocyte development in IL-7R alpha deficient mice. 2001. J. Leukocyte Biol. 34 Suppl. S 2001.
  5. Khaled AR, K Kim, K Muegge, L Fliegel, and SK Durum. Trophic factor withdrawal induces novel pathway: p38 MAPK activates NHE1 causing intracellular alkalinization, a novel step in apoptosis. 2001. FASEB J. 15 [5]: A1046.
  6. Kim K, AR Khaled, K Muegge, and SK Durum. Characterization of an IL-7 dependent thymocyte cell line: D1. 2001. FASEB J. 15 [5]: A1194.
  7. Khaled AR, K Kim, K Muegge, C Thompson, L Fliegel, and SK Durum. Trophic factor withdrawal induces novel pathway. 2001.Nature Biotechnology, Short Reports 12:93
  8. 8. Khaled AR, K Kim, K Muegge, C Thompson, L Fliegel, and SK Durum. Trophic factor withdrawal induces novel pathway. 2001. The Scientific World Journal 1(1Suppl 3):93.
  9. Khaled AR, K Kim, K Muegge, and SK Durum. Trophic factor withdrawal induces a novel pathway: p38 MAPK activates NHE1 resulting in intracellular alkalinization, an early step in apoptosis. 2000. Eur. Cytokine Netw. 11: 206.
  10. Khaled AR, K Kim, K Muegge, and SK Durum. 2000. IL-7 withdrawal induces a rise in intracellular pH through the NHE causing Bax translocation and a transient mitochondrial hyperpolarization. 2000.    FASEB J. 14 (6): A1090.
  11. Khaled AR, K Kim, K Muegge, and SK Durum. IL-7 withdrawal induces a rapid rise in intracellular pH causing: A) Bax translocation to mitochondria and B) Transient mitochondrial hyperpolarization. 1999. Cytokine 11(11): 975.
  12. Khaled AR, K Kim, K Muegge, and SK Durum. The trophic action of IL-7: Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. 1999. Cold Spring Harbor Symposia Quant. Biology, 64:93.
  13. Khaled AR, K Kim, D Reynolds, HA Young, R Youle, K Muegge, and SK Durum. IL-7 Induces Transcription of bcl-2 and bcl-XL and prevents mitochondrial translocation of Bax. 1999. FASEB J. 13 (5): A981.
  14. Welniak L.A, A Khaled, M Anver, D Reynolds, K Komschlies, R Wiltrout, H Young, BR Blazer, S Durum, and WJ Murphy. Non-immune action of interleukin-7: Intestinal crypt cells of interleukin-7 receptor deficient mice are highly sensitive to g-radiation damage. 1999. FASEB J. 13(5): A653.

Published as a pre-doctoral student from 1992-1997

  1. Khaled A, E Butfiloski, E Sobel, and J Schiffenbauer.. Motheaten viable mice (mev) have defects in NF-kB and IkB protein expression not found in BXSB mice. 1997. AAAAI/AAI/CIS Joint Meeting. San Francisco, CA.
  2. Khaled A, L Soares, E Butfiloski, I Stekman, E Sobel, and J Schiffenbauer.. Inhibition of the p50 subunit of NF-kB by antisense oligodeoxynucleotides reduces NF-kB expression and Ig synthesis in murine B cells. 1996. FASEB J. 10 (6):398.
  3. Khaled A, E Butfiloski, E Sobel, and J Schiffenbauer. Aberrant expression of the NF-kB and IkB proteins in motheaten viable mice has the potential to cause immune dysfunction. 1996. Arth. Rheum. 39(9):S29.
  4. Schiffenbauer J, A Rodriguez, and E Butfiloski. Aberrant expression of NF-kB in B cells from mev mice. 1994. Arth. Rheum. 37(9):S388.

Published as a research associate/technician 1985-1992

  1. Rodriguez A., M.R. Liebling, R. Russell, D. Carlberg, and J. Louie. Detection of polymorphic forms of the CD45RA exon in SLE patients and normal controls. Master’s Abstracts International, Dec. 1991.
  2. Nishio MJ, MR Liebling, A Rodriguez, L Siegel, and J Louie. 1990. Identification of Borrelia burgdorferi using interrupted PCR. Arth. Rheum. 33:B75.
  3. Liebling MR, CF Ware, A Rodriguez, and JS Louie. Cloned human T cell lines which specifically suppress anti-DNA production. 1987 Arth. Rheum. 30:S88.
  4. Keller MA, A Rodriguez, DM Reisinger, S Alvarez, and D Stewart. Transfer of tuberculin immunity from mother to infant. 1985. Clin. Res. 33:123A.